72 total
| Gene | Summary | First BL study | Other entities | QC result |
|---|---|---|---|---|
| ADAMTS5 | Tier 2 GE(burkhardtClinicalRelevanceMolecular2022?) | Burkhardt et al | ||
| ADNP | Tier 2 GE(burkhardtClinicalRelevanceMolecular2022?) | Burkhardt et al | ||
| AGO4 | Tier 2 GE(burkhardtClinicalRelevanceMolecular2022?) | Burkhardt et al | ||
| ARHGEF1 | Tier 2 GE(muppidiLossSignalingGa132014?) | Muppidi et al | ||
| BCL2 | Tier 2 GE(burkhardtClinicalRelevanceMolecular2022?), aSHM | Burkhardt et al | (morinFrequentMutationHistonemodifying2011?; sarkozyMutationalLandscapeGray2021?; tanakaFrequentIncidenceSomatic1992?) | |
| BTG1 | Tier 2 GE(burkhardtClinicalRelevanceMolecular2022?), FE(almasmoumFrequentLossBTG12021?), aSHM | Burkhardt et al | (drevalGeneticSubdivisionsFollicular2023?; morinFrequentMutationHistonemodifying2011?; sarkozyMutationalLandscapeGray2021?) | |
| C16orf48 | Tier 2 GE(schmitzBurkittLymphomaPathogenesis2012?) | Schmitz et al | ||
| CARD4 | Tier 2 GE(loveGeneticLandscapeMutations2012?) | Love et al | PASS | |
| CCNF | Tier 2 GE(abateDistinctViralMutational2015?) | Abate et al | (zhangGeneticHeterogeneityDiffuse2013?) | |
| CD79A | Tier 2 GE(burkhardtClinicalRelevanceMolecular2022?) | Burkhardt et al | (rossiCodingGenomeSplenic2012?) | |
| CD83 | Tier 2 GE(paneaWholeGenomeLandscape2019?), aSHM | Panea et al | (dunsCharacterizationDLBCLPMBL2021?; morinMutationalStructuralAnalysis2013?; russler-germainMutationsAssociatedProgression2023?) | PASS |
| CDC73 | Tier 2 GE(loveGeneticLandscapeMutations2012?) | Love et al | (reddyGeneticFunctionalDrivers2017?) | PASS |
| CDKN2A | Tier 2 GE(grandeGenomewideDiscoverySomatic2019?), FE(kannengiesserFunctionalStructuralGenetic2009?) | Grande et al | (morinMutationalStructuralAnalysis2013?; spinaGeneticsNodalMarginal2016?) | |
| CDKN2C | Tier 2 GE(thomasGeneticSubgroupsInform2023?) | Thomas et al | ||
| CHD4 | Tier 2 GE(burkhardtClinicalRelevanceMolecular2022?) | Burkhardt et al | ||
| CPXM2 | Tier 2 GE(burkhardtClinicalRelevanceMolecular2022?) | Burkhardt et al | ||
| CXCR4 | Tier 2 GE(paneaWholeGenomeLandscape2019?), FE(zmajkovicovaGenotypephenotypeCorrelationsWHIM2022?), aSHM | Panea et al | (khodabakhshiRecurrentTargetsAberrant2012?; krysiakRecurrentSomaticMutations2017?) | PASS |
| DHCR7 | Tier 2 GE(schmitzBurkittLymphomaPathogenesis2012?) | Schmitz et al | ||
| E2F2 | Tier 2 GE(burkhardtClinicalRelevanceMolecular2022?) | Burkhardt et al | ||
| EBF1 | Tier 2 GE(thomasGeneticSubgroupsInform2023?), FE(ramirez-komoSpontaneousLossLineage2017?), aSHM | Thomas et al | (bohleRoleEarlyBcell2013?; drevalGeneticSubdivisionsFollicular2023?; reichelFlowSortingExome2015?) | |
| EDNRB | Tier 2 GE(burkhardtClinicalRelevanceMolecular2022?) | Burkhardt et al | ||
| EHD1 | Tier 2 GE(thomasGeneticSubgroupsInform2023?) | Thomas et al | ||
| EIF4A1 | Tier 2 GE(paneaWholeGenomeLandscape2019?) | Panea et al | ||
| ELP2 | Tier 2 GE(schmitzBurkittLymphomaPathogenesis2012?) | Schmitz et al | ||
| EPPK1 | Tier 2 GE(paneaWholeGenomeLandscape2019?) | Panea et al | ||
| ERAP1 | Tier 2 GE(burkhardtClinicalRelevanceMolecular2022?) | Burkhardt et al | ||
| EXOSC6 | Tier 2 GE(schmitzBurkittLymphomaPathogenesis2012?) | Schmitz et al | ||
| EZH2 | Tier 2 GE(loveGeneticLandscapeMutations2012?), FE(sneeringerCoordinatedActivitiesWildtype2010?) | Love et al | (morinSomaticMutationsAltering2010?; mottokIntegrativeGenomicAnalysis2019?) | PASS |
| FLYWCH1 | Tier 2 GE(schmitzBurkittLymphomaPathogenesis2012?) | Schmitz et al | ||
| GGTLA4 | Tier 2 GE(loveGeneticLandscapeMutations2012?) | Love et al | PASS | |
| GTSE1 | Tier 2 GE(schmitzBurkittLymphomaPathogenesis2012?) | Schmitz et al | ||
| HIST1H3D | Tier 2 GE(paneaWholeGenomeLandscape2019?) | Panea et al | PASS | |
| HIST1H3I | Tier 2 GE(paneaWholeGenomeLandscape2019?) | Panea et al | (krysiakRecurrentSomaticMutations2017?) | PASS |
| HIST1H4J | Tier 2 GE(paneaWholeGenomeLandscape2019?) | Panea et al | (mottokIntegrativeGenomicAnalysis2019?) | PASS |
| HLA-DQB1 | Tier 2 GE(burkhardtClinicalRelevanceMolecular2022?) | Burkhardt et al | ||
| IGLL5 | Tier 2 GE(paneaWholeGenomeLandscape2019?), aSHM | Panea et al | (chapuyMolecularSubtypesDiffuse2018?; deschGenotypingCirculatingTumor2020?; russler-germainMutationsAssociatedProgression2023?) | PASS |
| IKZF3 | Tier 2 GE(paneaWholeGenomeLandscape2019?), FE(lazarianHotspotMutationTranscription2021?) | Panea et al | (morinFrequentMutationHistonemodifying2011?) | PASS |
| IRF8 | Tier 2 GE(paneaWholeGenomeLandscape2019?), FE(qiuIRF8mutantCellLymphoma2024?), aSHM | Panea et al | (morinFrequentMutationHistonemodifying2011?; mottokIntegrativeGenomicAnalysis2019?) | PASS |
| KANK2 | Tier 2 GE(schmitzBurkittLymphomaPathogenesis2012?) | Schmitz et al | ||
| KLHL26 | Tier 2 GE(burkhardtClinicalRelevanceMolecular2022?) | Burkhardt et al | ||
| KMT2C | Tier 2 GE(zhouSporadicEndemicBurkitt2019?) | Zhou et al | (sarkozyMutationalLandscapeGray2021?; zhangGeneticHeterogeneityDiffuse2013?; zhangGenomicLandscapeMantle2014?) | |
| MCL1 | Tier 2 GE(paneaWholeGenomeLandscape2019?) | Panea et al | (dunsCharacterizationDLBCLPMBL2021?; reddyGeneticFunctionalDrivers2017?) | PASS |
| MIR142 | Tier 2 GE(grandeGenomewideDiscoverySomatic2019?), FE(trissalMIR142LossofFunctionMutations2018?), aSHM | Grande et al | (kwanhianMicroRNA142Mutated202012?) | |
| MKI67 | Tier 2 GE(schmitzBurkittLymphomaPathogenesis2012?) | Schmitz et al | (russler-germainMutationsAssociatedProgression2023?) | |
| MYO18A | Tier 2 GE(schmitzBurkittLymphomaPathogenesis2012?) | Schmitz et al | ||
| NBEAL1 | Tier 2 GE(loveGeneticLandscapeMutations2012?) | Love et al | PASS | |
| NCOR2 | Tier 2 GE(schmitzBurkittLymphomaPathogenesis2012?) | Schmitz et al | (sarkozyMutationalLandscapeGray2021?; spinaGeneticsNodalMarginal2016?) | |
| NOA1 | Tier 2 GE(burkhardtClinicalRelevanceMolecular2022?) | Burkhardt et al | ||
| P2RY2 | Tier 2 GE(loveGeneticLandscapeMutations2012?) | Love et al | PASS | |
| PDCD11 | Tier 2 GE(schmitzBurkittLymphomaPathogenesis2012?) | Schmitz et al | ||
| PIM1 | Tier 2 GE(burkhardtClinicalRelevanceMolecular2022?), FE(kuoRolePIM1Ibrutinibresistant2016?), aSHM | Burkhardt et al | (drevalGeneticSubdivisionsFollicular2023?; dunsCharacterizationDLBCLPMBL2021?; pasqualucciHypermutationMultipleProtooncogenes2001?) | |
| PLCG2 | Tier 2 GE(paneaWholeGenomeLandscape2019?) | Panea et al | (fanComprehensiveCharacterizationDriver2020?) | PASS |
| PPP6R2 | Tier 2 GE(burkhardtClinicalRelevanceMolecular2022?) | Burkhardt et al | ||
| PREX1 | Tier 2 GE(burkhardtClinicalRelevanceMolecular2022?) | Burkhardt et al | ||
| RANBP6 | Tier 2 GE(loveGeneticLandscapeMutations2012?) | Love et al | PASS | |
| REV3L | Tier 2 GE(burkhardtClinicalRelevanceMolecular2022?) | Burkhardt et al | ||
| RNF144B | Tier 2 GE(paneaWholeGenomeLandscape2019?) | Panea et al | PASS | |
| RPL10 | Tier 2 GE(burkhardtClinicalRelevanceMolecular2022?) | Burkhardt et al | ||
| S1PR2 | Tier 2 GE(muppidiLossSignalingGa132014?), FE(muppidiLossSignalingGa132014?), aSHM | Muppidi et al | (drevalGeneticSubdivisionsFollicular2023?; morinFrequentMutationHistonemodifying2011?) | |
| SAL3 | Tier 2 GE(burkhardtClinicalRelevanceMolecular2022?) | Burkhardt et al | ||
| TET2 | Tier 2 GE(thomasGeneticSubgroupsInform2023?), FE(asmarGenomewideProfilingIdentifies2013?) | Thomas et al | (albuquerqueEnhancingKnowledgeDiscovery2017?) | |
| TOP2A | Tier 2 GE(schmitzBurkittLymphomaPathogenesis2012?) | Schmitz et al | ||
| TTN | Tier 2 GE(burkhardtClinicalRelevanceMolecular2022?) | Burkhardt et al | ||
| VWA7 | Tier 2 GE(burkhardtClinicalRelevanceMolecular2022?) | Burkhardt et al | ||
| WDR90 | Tier 2 GE(schmitzBurkittLymphomaPathogenesis2012?) | Schmitz et al | ||
| WHAMM | Tier 2 GE(schmitzBurkittLymphomaPathogenesis2012?) | Schmitz et al | ||
| WNK2 | Tier 2 GE(paneaWholeGenomeLandscape2019?) | Panea et al | PASS | |
| YY1AP1 | Tier 2 GE(schmitzBurkittLymphomaPathogenesis2012?) | Schmitz et al | ||
| ZAN | Tier 2 GE(burkhardtClinicalRelevanceMolecular2022?) | Burkhardt et al | ||
| ZBTB7A | Tier 2 GE(burkhardtClinicalRelevanceMolecular2022?) | Burkhardt et al | (reddyGeneticFunctionalDrivers2017?) | |
| ZFP36L1 | Tier 2 GE(paneaWholeGenomeLandscape2019?), aSHM | Panea et al | (morinFrequentMutationHistonemodifying2011?; reichelFlowSortingExome2015?) | PASS |
| ZNF85 | Tier 2 GE(burkhardtClinicalRelevanceMolecular2022?) | Burkhardt et al |
Citing
If you use the information or data from this site, please cite
Krysta Coyle, Kostiantyn Dreval, Daniel Hodson and Ryan D. Morin. Audit of B-cell cancer genes. Blood Adv (2025) 9 (8): 2019–2031.
Disclaimer
The content in these pages has been populated, in part, by an automated process. Although we have scrutinized every page to ensure accuracy, errors will inevitably exist. If you find an error please report it as an issue and we will address it.
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
Adapt — remix, transform, and build upon the material for any purpose, even commercially. The licensor cannot revoke these freedoms as long as you follow the license terms.
